Halozyme Therapeutics in (halo 0.25 03/01/27)
13F holders, Q2 2026 (June 30)11holders −3
2new positions
5sold out
$1.11avg. 13F price*
At the end of Q2 2026, 11 institutions reported holding Halozyme Therapeutics in (halo 0.25 03/01/27) in their 13F filings, down 3 from Q1 2026. 2 opened new positions and 5 sold out. The largest holders were TPG GP A, LLC ($11.1M), Rational Advisors, Inc. ($5.7M) and Focus Partners Wealth ($4.1M).
- Company
- Halozyme Therapeutics in (halo 0.25 03/01/27)
- CUSIP
- 40637HAD1
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $11K |
| Exits | 5 | $10.6M |
All 13F filers, Q1 2026 → Q2 2026: 2,152,931 shares bought and 10,226,000 shares sold, net −8,073,069 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| TPG GP A, LLC | 0.24% | No change | 10,000,000 | $11.1M |
| Rational Advisors, Inc. | 0.55% | Add +72.0% | 5,110,000 | $5.7M |
| Focus Partners Wealth | 0.00% | Reduce -1.1% | 3,711,000 | $4.1M |
| Oppenheimer Asset Management Inc. | 0.00% | Add +1.8% | 173,000 | $192K |
| &partners | 0.00% | No change | 130,000 | $144K |
| Mariner, LLC | 0.00% | No change | 59,000 | $66K |
| Stephens Inc. | 0.00% | No change | 53,000 | $59K |
| Commonwealth Equity Services, LLC | 0.00% | Reduce -15.0% | 17,000 | $19K |
| Cetera Investment Advisers | 0.00% | No change | 12,000 | $13K |
| Lanark Financial, Inc. | 0.00% | New | 8,000 | $9K |
| Laffer Tengler Investments, Inc. | 0.00% | New | 1,931 | $2K |
"% of holder's portfolio" is HALOZYME THERAPEUTICS IN (HALO 0.25 03/01/27)'s weight in each manager's 13F, not the share of Halozyme Therapeutics in (halo 0.25 03/01/27) the manager owns.